WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. (WXXWY) Stock Overview
Explore WuXi Biologics (Cayman) Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
13.3B
P/E Ratio
37.78
EPS (TTM)
$0.22
ROE
0.06%
WXXWY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of WuXi Biologics (Cayman) Inc. (WXXWY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $2.80.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 37.78 and a market capitalization of 13.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Zhisheng Chen
12,575
No. 108, Meiliang Road, Wuxi
2017